{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:45:28Z","timestamp":1793814328554,"version":"4.6.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Idiopathic inflammatory myopathies (IIMs) carry substantial extra-muscular comorbidities. The purpose of this review is to provide a focused synthesis of recent population-based data on the epidemiology of key comorbidities in IIMs: atherosclerotic cardiovascular disease (ASCVD), venous thromboembolism (VTE), psychiatric and neurocognitive disorders, and bone health.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>IIM patients have approximately two-fold increased risk of ASCVD and of other cardiovascular events, like VTE. These risks likely result from several factors, including chronic systemic inflammation, physical inactivity, treatment side effects. Anti-HMGCR immune necrotizing inflammatory myopathy (IMNM), is a subtype of IIM that requires special consideration regarding dyslipidemia management, where statin alternatives are necessary. Furthermore, psychiatric and neurocognitive comorbidities are common, and likely under-recognized among IIM patients, and perhaps especially so in inclusion body myositis (IBM) patients. Finally, IIM patients have an increased risk of accelerated bone loss likely due to systemic inflammation, muscle damage and physical inactivity, and glucocorticoid exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Cardiovascular care, psychiatric\/neurocognitive disorders, and osteopenia\/osteoporosis are highly prevalent and often underrecognized in IIMs. Effective management of these IIM-associated comorbidities requires a multidisciplinary, comprehensive care approach, and further work is needed to adapt existing risk-stratification and screening tools for the unique needs of IIMs patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001143","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T10:00:18Z","timestamp":1765188018000},"page":"76-82","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Comorbidities in idiopathic inflammatory myopathies: population-based evidence on risk subgroups and implications for delivery of care"],"prefix":"10.1097","volume":"38","author":[{"given":"Maria Emilia Romero","family":"Noboa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irakli","family":"Tskhakaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"R1-20260129","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41584-023-01033-0","article-title":"Epidemiology of the idiopathic inflammatory myopathies","volume":"19","author":"Khoo","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"R2-20260129","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(25)00233-9","article-title":"Advances in the classification and management of idiopathic inflammatory myopathies","volume":"24","author":"Raaphorst","year":"2025","journal-title":"Lancet Neurol"},{"key":"R3-20260129","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1093\/rheumatology\/keab851","article-title":"Cardiovascular events in adult polymyositis and dermatomyositis: a meta-analysis of observational studies","volume":"61","author":"Xiong","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R4-20260129","doi-asserted-by":"crossref","first-page":"119100","DOI":"10.1016\/j.atherosclerosis.2024.119100","article-title":"Risk of atherosclerosis-related diseases in polymyositis and dermatomyositis patients: a large-scale population-based study","volume":"401","author":"Fisher","year":"2025","journal-title":"Atherosclerosis"},{"key":"R5-20260129","doi-asserted-by":"crossref","first-page":"e005276","DOI":"10.1136\/rmdopen-2024-005276","article-title":"Cardiovascular events in patients with myositis: results from a French retrospective cohort","volume":"11","author":"Kasser","year":"2025","journal-title":"RMD Open"},{"key":"R6-20260129","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1007\/s10067-024-07109-w","article-title":"Atherosclerotic cardiovascular disease following a diagnosis of idiopathic inflammatory myopathy: analysis from a retrospective cohort in the TriNetX registry","volume":"43","author":"Allenzara","year":"2024","journal-title":"Clin Rheumatol"},{"key":"R7-20260129","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/annrheumdis-2017-211402","article-title":"Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study","volume":"77","author":"Dobloug","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R8-20260129","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/BOR.0000000000000442","article-title":"Cardiovascular involvement in myositis","volume":"29","author":"Diederichsen","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"R9-20260129","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1007\/s10067-023-06633-5","article-title":"Assessment of cardiovascular risk factors in patients with idiopathic inflammatory myopathies: a systematic review","volume":"42","author":"Gon\u00e7alves J\u00fanior","year":"2023","journal-title":"Clin Rheumatol"},{"key":"R10-20260129","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1080\/03009742.2025.2470011","article-title":"Cardiovascular risk and cardiac involvement in idiopathic inflammatory myopathies: insights from a cross-sectional Swedish single-centre study","volume":"54","author":"Hanna","year":"2025","journal-title":"Scand J Rheumatol"},{"key":"R11-20260129","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1007\/s10067-025-07530-9","article-title":"Cardiac involvement in established idiopathic inflammatory myopathy assessed by cardiac magnetic resonance mapping","volume":"44","author":"Yurchenko","year":"2025","journal-title":"Clin Rheumatol"},{"key":"R12-20260129","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025\u200aACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"R13-20260129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00296-025-05860-0","article-title":"Effectiveness of proprotein convertase subtilisin\/kexin type 9 inhibitors in managing hypercholesterolemia poststatin-associated immune-mediated necrotizing myopathy: report of five cases and literature review","volume":"45","author":"Yerolatsite","year":"2025","journal-title":"Rheumatol Int"},{"key":"R14-20260129","doi-asserted-by":"crossref","first-page":"e70175","DOI":"10.1111\/ene.70175","article-title":"Safety and effectiveness of PCSK9 inhibitors and inclisiran in patients with neuromuscular disorders and statin intolerance","volume":"32","author":"Theodorou","year":"2025","journal-title":"Eur J Neurol"},{"key":"R15-20260129","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/j.jacl.2024.04.039","article-title":"ASCVD risk reduction in patients with immune-mediated inflammatory disease: a retrospective quality assessment study","volume":"18","author":"Monzer","year":"2024","journal-title":"J Clin Lipidol"},{"key":"R16-20260129","doi-asserted-by":"crossref","first-page":"103447","DOI":"10.1016\/j.autrev.2023.103447","article-title":"Risk of venous thromboembolism in autoimmune diseases: a comprehensive review","volume":"22","author":"Menichelli","year":"2023","journal-title":"Autoimmun Rev"},{"key":"R17-20260129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/TCRM.S157085","article-title":"Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis","volume":"14","author":"Li","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"R18-20260129","doi-asserted-by":"crossref","first-page":"109203","DOI":"10.1016\/j.thromres.2024.109203","article-title":"Increased risk of pulmonary embolism in patients with dermatomyositis\/polymyositis, a retrospective cohort study from Israel","volume":"244","author":"Amster","year":"2024","journal-title":"Thromb Res"},{"key":"R19-20260129","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s10067-022-06140-z","article-title":"Thromboembolic events in idiopathic inflammatory myopathy: a retrospective study in China","volume":"41","author":"Chen","year":"2022","journal-title":"Clin Rheumatol"},{"key":"R20-20260129","article-title":"Predictors of thrombotic events in patients with idiopathic inflammatory myopathies","author":"Bae","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"R21-20260129","doi-asserted-by":"crossref","first-page":"152407","DOI":"10.1016\/j.semarthrit.2024.152407","article-title":"The differential role of SSa\/SSb and Ro52 antibodies in defining clinical phenotypes in idiopathic inflammatory myopathies","volume":"65","author":"Valle","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"R22-20260129","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"R23-20260129","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2023.1105","article-title":"Intravenous immunoglobulin and dermatomyositis-associated venous thromboembolism","volume":"159","author":"Rotrosen","year":"2023","journal-title":"JAMA Dermatol"},{"key":"R24-20260129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.rdc.2022.08.001","article-title":"Venous thromboembolism in the inflammatory rheumatic diseases","volume":"49","author":"Misra","year":"2023","journal-title":"Rheum Dis Clin North Am"},{"key":"R25-20260129","doi-asserted-by":"crossref","first-page":"103455","DOI":"10.1016\/j.autrev.2023.103455","article-title":"Idiopathic inflammatory myopathies - the burden of disease: cohort analysis focusing on damage and comorbidities","volume":"22","author":"Campar","year":"2023","journal-title":"Autoimmun Rev"},{"key":"R26-20260129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-025-00458-2","article-title":"Patient reported physical function, mental health, and treatment patterns in dermatomyositis: survey results from a cross-sectional study of adult dermatomyositis patients","volume":"9","author":"Christopher-Stine","year":"2025","journal-title":"BMC Rheumatol"},{"key":"R27-20260129","doi-asserted-by":"crossref","first-page":"e097829","DOI":"10.1136\/bmjopen-2024-097829","article-title":"Epidemiology and risk of psychiatric disorders in patients with polymyositis and dermatomyositis: a nationwide population-based cohort study in Taiwan","volume":"15","author":"Lee","year":"2025","journal-title":"BMJ Open"},{"key":"R30-20260129","doi-asserted-by":"crossref","first-page":"100199","DOI":"10.1016\/j.dscb.2025.100199","article-title":"Mind over matter? A cross-sectional study exploring the influence of depression versus physical disability on patient-reported wellbeing in inclusion body myositis","volume":"17","author":"Nunn","year":"2025","journal-title":"Brain Disord"},{"key":"R31-20260129","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1186\/s12888-025-06996-w","article-title":"Prevalence of anxiety, depression, and posttraumatic stress disorder during the COVID-19 lockdown in patients with rheumatoid arthritis or systemic lupus erythematosus: a systematic review","volume":"25","author":"Eslami","year":"2025","journal-title":"BMC Psychiatry"},{"key":"R32-20260129","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jpsychires.2025.03.020","article-title":"Beyond rheumatoid arthritis: a meta-analysis of the prevalence of anxiety and depressive disorders in rheumatoid arthritis","volume":"184","author":"Drakes","year":"2025","journal-title":"J Psychiatr Res"},{"key":"R33-20260129","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tips.2025.01.005","article-title":"Emerging mechanisms and therapeutics in inflammatory muscle diseases","volume":"46","author":"Wischnewski","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"R34-20260129","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"R35-20260129","doi-asserted-by":"crossref","first-page":"8369","DOI":"10.3390\/ijms26178369","article-title":"Idiopathic inflammatory myopathy\u2014molecular mechanisms underlying its pathogenesis and physical therapy effects","volume":"26","author":"Markowska","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R36-20260129","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X231181968","article-title":"Reduced bone mineral density in patients with idiopathic inflammatory myopathies: a case-control study","volume":"15","author":"Tang","year":"2023","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R37-20260129","doi-asserted-by":"crossref","first-page":"e15268","DOI":"10.1111\/1756-185X.15268","article-title":"Management of bone health in idiopathic inflammatory myopathies: a two-center audit in the United Kingdom and Hong Kong","volume":"27","author":"Thumbe","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"R38-20260129","doi-asserted-by":"crossref","first-page":"e15451","DOI":"10.1111\/1756-185X.15451","article-title":"Unveiling the elevated risk of osteoporosis and fractures in idiopathic inflammatory myopathies: emphasizing awareness of modifiable risk factors","volume":"27","author":"Coskun Benlidayi","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"R39-20260129","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/jhn.13287","article-title":"Nutritional interventions as modulators of the disease activity for idiopathic inflammatory myopathies: a scoping review","volume":"37","author":"S\u00e1nchez-Rosales","year":"2024","journal-title":"J Hum Nutr Diet"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T06:00:15Z","timestamp":1769666415000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001143","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]}}}